Artisan Partners Limited Partnership Has $59.56 Million Stock Position in Repligen Co. (NASDAQ:RGEN)

Artisan Partners Limited Partnership trimmed its position in shares of Repligen Co. (NASDAQ:RGEN) by 5.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 413,747 shares of the biotechnology company’s stock after selling 23,544 shares during the period. Artisan Partners Limited Partnership’s holdings in Repligen were worth $59,555,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Signaturefd LLC grew its stake in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 124 shares during the last quarter. Resources Management Corp CT ADV bought a new position in Repligen during the 3rd quarter worth $37,000. Quarry LP raised its stake in Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 239 shares in the last quarter. UMB Bank n.a. raised its position in shares of Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 110 shares in the last quarter. Finally, Global Retirement Partners LLC lifted its stake in Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 129 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Down 1.7 %

Shares of NASDAQ RGEN opened at $137.12 on Friday. The business’s fifty day moving average price is $154.75 and its 200-day moving average price is $148.22. Repligen Co. has a one year low of $113.50 and a one year high of $187.25. The stock has a market capitalization of $7.70 billion, a PE ratio of -268.86, a P/E/G ratio of 4.54 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, equities research analysts anticipate that Repligen Co. will post 1.72 EPS for the current year.

Insider Buying and Selling

In other news, Director Margaret Pax bought 250 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the transaction, the director now directly owns 1,043 shares of the company’s stock, valued at $157,169.67. This represents a 31.53 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Canaccord Genuity Group boosted their target price on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. HC Wainwright reissued a “buy” rating and set a $180.00 target price on shares of Repligen in a report on Friday, February 21st. TD Cowen began coverage on shares of Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective on the stock. Canaccord Genuity Group began coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Finally, Royal Bank of Canada increased their target price on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Repligen currently has an average rating of “Hold” and a consensus target price of $178.64.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.